EP4729120A2 — Methods and compositions for treating a bleeding event in a subject having hemophilia
Assigned to Genzyme Corp · Expires 2026-04-22 · 0y expired
What this patent protects
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpincl gene, and methods of using such iRNA, e.g., dsRNA, compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without Inhibitors).
USPTO Abstract
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpincl gene, and methods of using such iRNA, e.g., dsRNA, compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without Inhibitors).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.